JAK1 and systemic lupus erythematosus: It is interesting to highlight the fact that both baricitinib (a JAK1/2 inhibitor) and tofacitinib (a JAK1/3 inhibitor) treatments of mouse-isolated or human-isolated B cells have led to strong reductions of ABC/DN percentages [8], thus strengthening the scenario of JAK inhibitors being beneficial to SLE patients.